<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02006927</url>
  </required_header>
  <id_info>
    <org_study_id>2013-420</org_study_id>
    <nct_id>NCT02006927</nct_id>
  </id_info>
  <brief_title>A Pilot Study of the Feasibility of Chronic Cavernous Nerve Stimulation to Promote Regeneration and Erectile Function</brief_title>
  <official_title>A Pilot Study of the Feasibility of Chronic Cavernous Nerve Stimulation to Promote Neural Regeneration and Erectile Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kenneth M Peters, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>William Beaumont Hospitals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>William Beaumont Hospitals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to evaluate electrical stimulation of nerves responsible for&#xD;
      erectile function after surgery to remove the prostate (prostatectomy). Electrical&#xD;
      stimulation of the nerves responsible for erectile function is experimental. The&#xD;
      investigators hypothesize that the subjects can tolerate nerve stimulation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the study is to explore the feasibility of using an implantable&#xD;
      neurostimulation device/leads post radical robotic prostatectomy as a method for enhancing&#xD;
      neural recovery/penile rehabilitation and/or erectile dysfunction treatment. This will be a&#xD;
      single center pilot study of up to 10 patients. The leads will be placed and stimulated&#xD;
      intraoperatively to assess proper placement and stimulation parameters needed to achieve&#xD;
      change in penile length and/or circumference. One week post operatively, the leads will be&#xD;
      connected to an external stimulator device and activated. Subjects will be instructed to&#xD;
      stimulate each lead by turning on the device each day for up to six weeks. The leads will be&#xD;
      removed at six weeks post operative and subjects will be followed for up to two years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of Enrollment&#xD;
  </why_stopped>
  <start_date type="Actual">July 2014</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability of Nerve Stimulation</measure>
    <time_frame>6 weeks</time_frame>
    <description>Evaluate the safety and tolerability of chronic cavernous nerve stimulation post radical prostatectomy by measuring the incidence of major complications that may include lead removal, infection at the site or painful stimulation requiring lead removal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of Nerve Stimulation</measure>
    <time_frame>24 months</time_frame>
    <description>Explore the potential efficacy of chronic cavernous nerve stimulation on the return of erectile function post radical prostatectomy. Measures to assess efficacy include direct response to stimulation, changes in penile tumescence (girth) and sensory perception.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Nerve Stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placement and stimulation of implantable neurostimulation device/leads post radical robotic prostatectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nerve Stimulation</intervention_name>
    <description>Placement and stimulation of implantable neurostimulation device/leads post radical robotic prostatectomy</description>
    <arm_group_label>Nerve Stimulation</arm_group_label>
    <other_name>Lead stimulation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Scheduled for a robotic radical prostatectomy procedure with bilateral nerve sparing.&#xD;
&#xD;
          2. Sexually functional preoperatively as defined by a Sexual Health Inventory For Men&#xD;
             (SHIM) score of greater than 21 at baseline off any phosphodiesterase 5 inhibitors.&#xD;
&#xD;
          3. Without erectile dysfunction treatment in the 12 months prior to radical&#xD;
             prostatectomy.&#xD;
&#xD;
          4. Willing to stop phosphodiesterase 5 inhibitor that has only been started&#xD;
             prophylactically to promote penile rehabilitation after prostatectomy.&#xD;
&#xD;
          5. Age 40 to 80 years of age.&#xD;
&#xD;
          6. Stable on all medications for at least 6 weeks prior to completing baseline measures&#xD;
             and be willing to remain on those medications with no dose adjustments expected for 6&#xD;
             weeks post-implantation.&#xD;
&#xD;
          7. An appropriate candidate for the surgical procedure required for this study.&#xD;
&#xD;
          8. Willing and able to comply with all study related procedures and visits, and making&#xD;
             accurate daily entries into a diary for approximately 6 weeks post radical&#xD;
             prostatectomy (lead stimulation phase).&#xD;
&#xD;
          9. Capable of reading and understanding patient information materials and giving written&#xD;
             informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have been diagnosed with vascular insufficiency to any pelvic blood vessels.&#xD;
&#xD;
          2. Have prior surgical implantation of penile prosthesis, or other prior major pelvic&#xD;
             surgery.&#xD;
&#xD;
          3. History of significant pelvic trauma.&#xD;
&#xD;
          4. Are current substance abusers including illicit drugs or use narcotics more than 15&#xD;
             days/month.&#xD;
&#xD;
          5. Have a significant psychiatric disorder or under current treatment with antipsychotic&#xD;
             or antidepressive medications.&#xD;
&#xD;
          6. Have previously not tolerated an implanted medical device and subsequently required&#xD;
             explant of the device for any reason other than device malfunction.&#xD;
&#xD;
          7. Have a condition currently requiring or likely to require the use of MRI or diathermy.&#xD;
&#xD;
          8. Currently have an active implantable device.&#xD;
&#xD;
          9. Have participated in any drug or device trial in the last 4 weeks or plan to&#xD;
             participate in any other drug or device study during the next 24 months.&#xD;
&#xD;
         10. Have metabolic or immunodeficiency disorders related to recurrent infections,&#xD;
             specifically including but not limited to diabetes mellitus, HIV, disorders requiring&#xD;
             chronic or high dose corticosteroids, or connective tissue disorders.&#xD;
&#xD;
         11. Have Peyronies disease.&#xD;
&#xD;
         12. Subject possesses any other characteristics that, per the investigator's judgment,&#xD;
             deems them unsuitable (eg increases risk, impairs data collection, etc) for the&#xD;
             procedure/study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth M Peters, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>William Beaumont Hospitals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>December 4, 2013</study_first_submitted>
  <study_first_submitted_qc>December 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2013</study_first_posted>
  <results_first_submitted>September 9, 2020</results_first_submitted>
  <results_first_submitted_qc>September 9, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 1, 2020</results_first_posted>
  <last_update_submitted>September 30, 2020</last_update_submitted>
  <last_update_submitted_qc>September 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>William Beaumont Hospitals</investigator_affiliation>
    <investigator_full_name>Kenneth M Peters, MD</investigator_full_name>
    <investigator_title>Chief of Urology</investigator_title>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Nerve Stimulation</title>
          <description>Placement and stimulation of implantable neurostimulation device/leads post radical robotic prostatectomy&#xD;
Nerve Stimulation: Placement and stimulation of implantable neurostimulation device/leads post radical robotic prostatectomy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline data was collected on all 3 participants before they withdrew from study</population>
      <group_list>
        <group group_id="B1">
          <title>Nerve Stimulation</title>
          <description>Placement and stimulation of implantable neurostimulation device/leads post radical robotic prostatectomy&#xD;
Nerve Stimulation: Placement and stimulation of implantable neurostimulation device/leads post radical robotic prostatectomy</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.3" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Tolerability of Nerve Stimulation</title>
        <description>Evaluate the safety and tolerability of chronic cavernous nerve stimulation post radical prostatectomy by measuring the incidence of major complications that may include lead removal, infection at the site or painful stimulation requiring lead removal.</description>
        <time_frame>6 weeks</time_frame>
        <population>All participants withdrawn from study prior to any data collection or analysis. No data analyzed to report.</population>
        <group_list>
          <group group_id="O1">
            <title>Nerve Stimulation</title>
            <description>Placement and stimulation of implantable neurostimulation device/leads post radical robotic prostatectomy&#xD;
Nerve Stimulation: Placement and stimulation of implantable neurostimulation device/leads post radical robotic prostatectomy</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerability of Nerve Stimulation</title>
          <description>Evaluate the safety and tolerability of chronic cavernous nerve stimulation post radical prostatectomy by measuring the incidence of major complications that may include lead removal, infection at the site or painful stimulation requiring lead removal.</description>
          <population>All participants withdrawn from study prior to any data collection or analysis. No data analyzed to report.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy of Nerve Stimulation</title>
        <description>Explore the potential efficacy of chronic cavernous nerve stimulation on the return of erectile function post radical prostatectomy. Measures to assess efficacy include direct response to stimulation, changes in penile tumescence (girth) and sensory perception.</description>
        <time_frame>24 months</time_frame>
        <population>All participants withdrawn from study prior to any data collection or analysis. No data analyzed to report.</population>
        <group_list>
          <group group_id="O1">
            <title>Nerve Stimulation</title>
            <description>Placement and stimulation of implantable neurostimulation device/leads post radical robotic prostatectomy&#xD;
Nerve Stimulation: Placement and stimulation of implantable neurostimulation device/leads post radical robotic prostatectomy</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of Nerve Stimulation</title>
          <description>Explore the potential efficacy of chronic cavernous nerve stimulation on the return of erectile function post radical prostatectomy. Measures to assess efficacy include direct response to stimulation, changes in penile tumescence (girth) and sensory perception.</description>
          <population>All participants withdrawn from study prior to any data collection or analysis. No data analyzed to report.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 months</time_frame>
      <desc>Adverse events (AEs) assessment will be performed at each study visit following implantation through 24 months. All AEs will be initially reviewed by the Principal Investigator (PI), The PI will determine severity and causality. AEs will be reported per institutional and FDA requirements.</desc>
      <group_list>
        <group group_id="E1">
          <title>Nerve Stimulation</title>
          <description>Placement and stimulation of implantable neurostimulation device/leads post radical robotic prostatectomy&#xD;
Nerve Stimulation: Placement and stimulation of implantable neurostimulation device/leads post radical robotic prostatectomy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea/vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hiatal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Bladder leak</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Device lead migration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Infected pelvic hematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was terminated early after technical problems with device caused device removal in all 3 enrolled subjects and withdrawal of all 3 enrolled subjects prior to data collection or analysis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Deborah Hasenau, RN</name_or_title>
      <organization>William Beaumont Hospitals</organization>
      <phone>248 551-0804</phone>
      <email>deborah.hasenau@beaumont.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

